OROPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for OROPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OROPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for OROPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo cancer therapy trial halted early
Disease control TerminatedThis study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, and lung cancer. The trial enrolled 77 adu…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Peptide vaccine study in head and neck cancer halted early
Knowledge-focused TerminatedThis study tested a peptide-based immunotherapy given before surgery in 17 adults with head and neck cancer. The goal was to see if the vaccine could safely boost the immune system's attack on tumors. The trial was terminated early, so results are limited.
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC